GRAL vs. AHCO, CDNA, TDOC, AVAH, PNTG, VRDN, INNV, CSTL, WGS, and FLGT
Should you be buying Grail stock or one of its competitors? The main competitors of Grail include AdaptHealth (AHCO), CareDx (CDNA), Teladoc Health (TDOC), Aveanna Healthcare (AVAH), The Pennant Group (PNTG), Viridian Therapeutics (VRDN), InnovAge (INNV), Castle Biosciences (CSTL), GeneDx (WGS), and Fulgent Genetics (FLGT). These companies are all part of the "healthcare" industry.
AdaptHealth (NASDAQ:AHCO) and Grail (NASDAQ:GRAL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, community ranking, profitability, institutional ownership, valuation, risk, dividends and media sentiment.
Grail has a net margin of 0.00% compared to AdaptHealth's net margin of -21.20%. AdaptHealth's return on equity of 9.58% beat Grail's return on equity.
AdaptHealth received 78 more outperform votes than Grail when rated by MarketBeat users.
82.7% of AdaptHealth shares are owned by institutional investors. 4.4% of AdaptHealth shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
AdaptHealth presently has a consensus target price of $10.70, suggesting a potential downside of 3.60%. Given AdaptHealth's higher possible upside, equities analysts plainly believe AdaptHealth is more favorable than Grail.
Grail has lower revenue, but higher earnings than AdaptHealth.
In the previous week, AdaptHealth had 8 more articles in the media than Grail. MarketBeat recorded 14 mentions for AdaptHealth and 6 mentions for Grail. AdaptHealth's average media sentiment score of 0.50 beat Grail's score of 0.39 indicating that AdaptHealth is being referred to more favorably in the media.
Summary
AdaptHealth beats Grail on 10 of the 12 factors compared between the two stocks.
Get Grail News Delivered to You Automatically
Sign up to receive the latest news and ratings for GRAL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GRAL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
